Co-regulation of microglial subgroups in Alzheimer's amyloid pathology: Implications for diagnosis and drug...

Area of Science:

• Neuroimmunology
• Systems Biology
• Neurodegenerative Diseases

Background:

• Alzheimer's disease (AD) is a leading cause of dementia, characterized by progressive neurodegeneration.
• Neuroinflammation, driven by microglial responses, plays a critical role in AD progression.
• The interplay between pro-inflammatory and anti-inflammatory microglial subgroups in early AD is not well understood.

Purpose of the Study:

• To investigate the regulatory relationships between pro- and anti-inflammatory microglial subgroups in Alzheimer's disease.
• To explore the role of the Trem2 signaling pathway in microglial responses.
• To establish a systems biology framework for understanding microglial co-regulation in AD.

Main Methods:

• Comparative transcriptomics and bioinformatics analyses.
• Fluorescence-activated cell sorting (FACS) and gene regulation analysis.
• Immunoassays to identify co-regulated microglial subgroups and upstream regulators.

Main Results:

• The Trem2 signaling pathway was implicated in an anti-inflammatory microglial subgroup.
• Microglial subgrouping and microgliosis preceded cytokine upregulation in early amyloid pathology.
• Anti-inflammatory and pro-inflammatory microglial subgroups were co-regulated by shared upstream regulators, suggesting a mechanism for balancing microglial activation.

Conclusions:

• This study reveals previously unrecognized co-regulation of microglial subgroups in AD.
• This co-regulation may balance microglial activation and contribute to chronic neuroinflammation in AD.
• The findings provide a systems biology framework that could inform improved diagnostic markers and immunotherapeutic strategies for AD.